文献速递淋巴瘤

HDAC1在ALK阳性间变性大细胞淋巴瘤中发挥抑癌作用:对HDAC抑制剂治疗的启示

HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy.
PubMed 文献 · Leukemia · 2025-04-02

本文在NPM::ALK阳性间变性大细胞淋巴瘤(ALCL)小鼠模型中研究HDAC抑制的作用。短期全身性使用HDAC抑制剂恩替诺特可推迟或阻止淋巴瘤发生,但T细胞特异性敲除Hdac1或Hdac2反而加速NPM::ALK驱动的淋巴瘤发生,其中Hdac1缺失效应更明显。研究提示HDAC1和HDAC2在T细胞中具有抑癌功能,但全身性HDAC抑制仍可能改善当前治疗结局。

要点

  • 在ALCL小鼠模型中,短期全身性恩替诺特治疗可推迟或阻止淋巴瘤发生。
  • T细胞特异性敲除Hdac1或Hdac2加速NPM::ALK驱动淋巴瘤发生,Hdac1缺失效应更明显。
  • Hdac1缺失选择性扰动T细胞分化与信号相关转录程序,并上调PDGFRB等致癌信号通路。

核心结论

  • HDAC1和HDAC2在ALCL发生过程中于T细胞中发挥抑癌功能。
  • 全身性药理抑制HDAC仍可能改善当前治疗结局。

研究设计与样本

  • 研究在NPM::ALK阳性ALCL小鼠模型中进行,采用HDAC抑制剂恩替诺特短期全身性给药。
  • 采用条件性基因敲除方法,在T细胞中特异性删除Hdac1或Hdac2。
  • 整合基因表达与染色质可及性数据进行分析。

主要发现

  • 在癌前ALCL小鼠模型中,短期全身性恩替诺特治疗推迟或甚至阻止淋巴瘤发生,尽管NPM::ALK融合癌基因高表达。
  • T细胞特异性删除Hdac1或Hdac2显著加速NPM::ALK驱动的淋巴瘤发生,Hdac1缺失效应更明显。
  • Hdac1缺失选择性扰动对T细胞分化和信号至关重要的细胞类型特异性转录程序。
  • 包括PDGFRB信号在内的多条致癌信号通路高度上调。

临床怎么用

  • 作者认为HDAC1和HDAC2在T细胞中具有抑癌功能。
  • 作者认为全身性药理抑制HDAC仍可能改善当前治疗结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Histone deacetylases (HDACs) are frequently deregulated in cancer, and several HDAC inhibitors (HDACi) have gained approval for treating peripheral T cell lymphomas. Here, we investigated the effects of pharmacological or genetic HDAC inhibition on NPM::ALK positive anaplastic large cell lymphoma (ALCL) development to assess the potential use of HDACi for the treatment of this disease. Short-term systemic pharmacological inhibition of HDACs using the HDACi Entinostat in a premalignant ALCL mouse model postponed or even abolished lymphoma development, despite high expression of the NPM::ALK fusion oncogene. To further disentangle the effects of systemic HDAC inhibition from thymocyte intrinsic effects, conditional genetic deletions of HDAC1 and HDAC2 enzymes were employed. In sharp contrast, T cell-specific deletion of Hdac1 or Hdac2 in the ALCL mouse model significantly accelerated NPM::ALK-driven lymphomagenesis, with Hdac1 loss having a more pronounced effect. Integration of gene expression and chromatin accessibility data revealed that Hdac1 deletion selectively perturbed cell type-specific transcriptional programs, crucial for T cell differentiation and signaling. Moreover, multiple oncogenic signaling pathways, including PDGFRB signaling, were highly upregulated. Our findings underscore the tumor-suppressive function of HDAC1 and HDAC2 in T cells during ALCL development. Nevertheless, systemic pharmacological inhibition of HDACs could still potentially improve current therapeutic outcomes.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Zrimšek M, Draganić K, Malzer A, et al. HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy. Leukemia. 2025. PMID: 40175628. doi:10.1038/s41375-025-02584-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。